{"name":"Ferring Pharmaceuticals","slug":"ferring-pharmaceuticals","ticker":"","exchange":"","domain":"ferring.com","description":"","hq":"Saint-Prex, Switzerland","founded":0,"employees":"","ceo":"","sector":"Reproductive Medicine / GI / Urology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":2800000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-06-02","label":"Lutrepulse Phase 3 readout (Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8)","drug":"Lutrepulse","drugSlug":"lutrepulse","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-07-19","label":"Pentasa Phase 3 readout (Ulcerative Colitis (UC))","drug":"Pentasa","drugSlug":"pentasa","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-03-01","label":"Lutrepulse Phase 3 readout (Metastatic Breast Cancer)","drug":"Lutrepulse","drugSlug":"lutrepulse","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-12-31","label":"Lutrepulse Phase 3 readout (Prostate Cancer)","drug":"Lutrepulse","drugSlug":"lutrepulse","type":"phase3_readout","sentiment":"neutral"},{"date":"2028-05-31","label":"Lutrepulse Phase 3 readout (Prostate Carcinoma)","drug":"Lutrepulse","drugSlug":"lutrepulse","type":"phase3_readout","sentiment":"neutral"},{"date":"2029-03-30","label":"Lutrepulse Phase 2 readout (Prostate Cancer, Oligometastasis)","drug":"Lutrepulse","drugSlug":"lutrepulse","type":"phase3_readout","sentiment":"neutral"},{"date":"2030-03-29","label":"Lutrepulse Phase 3 readout (Biochemically Recurrent Prostate Cancer)","drug":"Lutrepulse","drugSlug":"lutrepulse","type":"phase3_readout","sentiment":"neutral"},{"date":"2030-12-31","label":"Pentasa Phase 2 readout (Ulcerative Colitis, Fecal Microbiota Transplantation)","drug":"Pentasa","drugSlug":"pentasa","type":"phase3_readout","sentiment":"neutral"},{"date":"2035-12-01","label":"Lutrepulse Phase 2 readout (Prostate Cancer (Adenocarcinoma), Prostate Brachytherapy)","drug":"Lutrepulse","drugSlug":"lutrepulse","type":"phase3_readout","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":17,"colorKey":"oncology","drugs":[{"name":"Crinone","genericName":"Crinone","slug":"crinone","indication":"Other","status":"marketed"},{"name":"Novarel","genericName":"Novarel","slug":"novarel","indication":"Other","status":"discontinued"},{"name":"Antocin Ii","genericName":"ATOSIBAN","slug":"atosiban","indication":"Prevention of Premature Labor","status":"marketed"},{"name":"Choriongonadotropin","genericName":"Choriongonadotropin","slug":"choriongonadotropin","indication":"Other","status":"marketed"},{"name":"FE 999326","genericName":"FE 999326","slug":"fe-999326","indication":"Other","status":"phase_3"},{"name":"Glycerine","genericName":"Glycerine","slug":"glycerine","indication":"Constipation","status":"marketed"},{"name":"Lutrepulse","genericName":"Lutrepulse","slug":"lutrepulse","indication":"Other","status":"discontinued"},{"name":"MINIRIN Oral Lyophilisate","genericName":"MINIRIN Oral Lyophilisate","slug":"minirin-oral-lyophilisate","indication":"Other","status":"marketed"},{"name":"Menotrophin","genericName":"Menotrophin","slug":"menotrophin","indication":"Other","status":"marketed"},{"name":"Merotocin","genericName":"Merotocin","slug":"merotocin","indication":"Other","status":"discontinued"},{"name":"Norprolac","genericName":"Norprolac","slug":"norprolac","indication":"Other","status":"phase_2"},{"name":"PICOPREP","genericName":"PICOPREP","slug":"picoprep","indication":"Other","status":"marketed"},{"name":"Pabal","genericName":"CARBETOCIN","slug":"carbetocin","indication":"Atony of uterus","status":"marketed"},{"name":"Pentasa","genericName":"Pentasa","slug":"pentasa","indication":"Other","status":"discontinued"},{"name":"Primary nocturnal enuresis","genericName":"Primary nocturnal enuresis","slug":"primary-nocturnal-enuresis","indication":"Other","status":"marketed"},{"name":"REBYOTA™","genericName":"REBYOTA™","slug":"rebyota","indication":"Other","status":"marketed"},{"name":"Recombinant Human Follitropin Alfa","genericName":"Recombinant Human Follitropin Alfa","slug":"recombinant-human-follitropin-alfa","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"Crinone","genericName":"Crinone","slug":"crinone","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Novarel","genericName":"Novarel","slug":"novarel","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Antocin Ii","genericName":"ATOSIBAN","slug":"atosiban","phase":"marketed","mechanism":"Vasopressin V1a receptor","indications":["Prevention of Premature Labor"],"catalyst":""},{"name":"Choriongonadotropin","genericName":"Choriongonadotropin","slug":"choriongonadotropin","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"FE 999326","genericName":"FE 999326","slug":"fe-999326","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Glycerine","genericName":"Glycerine","slug":"glycerine","phase":"marketed","mechanism":"Small molecule","indications":["Constipation"],"catalyst":""},{"name":"Lutrepulse","genericName":"Lutrepulse","slug":"lutrepulse","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MINIRIN Oral Lyophilisate","genericName":"MINIRIN Oral Lyophilisate","slug":"minirin-oral-lyophilisate","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Menotrophin","genericName":"Menotrophin","slug":"menotrophin","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Merotocin","genericName":"Merotocin","slug":"merotocin","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Norprolac","genericName":"Norprolac","slug":"norprolac","phase":"phase_2","mechanism":"Adrenergic receptor alpha-1, Adrenergic receptor alpha-2, Dopamine receptor","indications":[],"catalyst":""},{"name":"PICOPREP","genericName":"PICOPREP","slug":"picoprep","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Pabal","genericName":"CARBETOCIN","slug":"carbetocin","phase":"marketed","mechanism":"Oxytocin receptor","indications":["Atony of uterus","Prader-Willi syndrome"],"catalyst":""},{"name":"Pentasa","genericName":"Pentasa","slug":"pentasa","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Primary nocturnal enuresis","genericName":"Primary nocturnal enuresis","slug":"primary-nocturnal-enuresis","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"REBYOTA™","genericName":"REBYOTA™","slug":"rebyota","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Recombinant Human Follitropin Alfa","genericName":"Recombinant Human Follitropin Alfa","slug":"recombinant-human-follitropin-alfa","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTE1CWkhaZ3pNbXBhOFQ5cnpIeHVlRkQ2TXpYLWNQamZDN0JqUGZ1eWxtMWd0WWdfM2twRjdsV1FGdG5FQTFkTzIzY2FFbnpkN1lma3NjWk96VEhwWVZFYjBTVWpwODItMllzb2ltTjJEOA?oc=5","date":"2026-03-13","type":"earnings","source":"medwatch.com","summary":"Ferring's revenue exceeds EUR 2.5bn for the first time - medwatch.com","headline":"Ferring's revenue exceeds EUR 2.5bn for the first time","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5LQ19kSGlQWnlFb2xNckFrUmE2M1Rvd2VLbTd6UWdRdTJYcm1Cb0g4ak5xQnVqQTdtd0hRbW0xU2hMR3dpRFJYM29HUEZqaXdHdldQWW5CdWdfdjBfUXc0b2VNdjFUMWdsblB0Zk9B0gFyQVVfeXFMTXpxVk5yV2FMR050ZUdydWJXMzFLLWxEOHdtazhHVWJBYWNSaVNJc3dKMlR6eTk3OFE4RnVFSmhLUnVjcHhSVEVMdjVhVFRESmhweU5idFNfVVAxM3RJaUNCWHM3LVZaMWZ4S0pVTHRJY2tB?oc=5","date":"2026-01-12","type":"pipeline","source":"koreabiomed.com","summary":"Hanmi Pharm and Ferring Korea agree on joint sales of nocturia treatment - koreabiomed.com","headline":"Hanmi Pharm and Ferring Korea agree on joint sales of nocturia treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQUl9Zc0ZEWEg2TnR4c0xSMWc3OHJoQVcxVGFfejlvWVdEajRWT3B4VTEyOVFmMDZ5OVpjUUJBRkEwaTcxZHFYWFlvRkVOdHB5RDU4QzBWS05rcUN3Qlp4cGZtUTAtYkxBYXUzeDNVZ0tXTjBMaEVvMXEtc2lROF9La1RFenJHdHBKN2dKZWRRa2RHR01KZ3gwWmtoYU9wQTlmZkZZNWp0cnBVbjlGdDdVc3VFU1J0TGJx?oc=5","date":"2025-12-03","type":"pipeline","source":"Fierce Pharma","summary":"Workplaces labor to keep staff as fertility support falls short, Ferring survey finds - Fierce Pharma","headline":"Workplaces labor to keep staff as fertility support falls short, Ferring survey finds","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9MLTVLTTI0OWhWVlNCTHRpcThGOUtjOTcyRHN1Wkw3eWV0OVhxRGNiald1OS1MWmEtYkhGaV9zU1MwNHlRRXY2ZEFlUmdyNGlnMk9meU5UY2dqSFJ0Ti1MdUJnaHVKa0dvaTR4U3JR?oc=5","date":"2025-10-27","type":"pipeline","source":"NJBIZ","summary":"Ferring to cut 64 jobs at Parsippany HQ amid global layoffs - NJBIZ","headline":"Ferring to cut 64 jobs at Parsippany HQ amid global layoffs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPLTI0SlFtVEdwdVpfNGVjbnhxUHdtN1BadVYxRUNkSjFvVTNGM3Y0TDJUR1d1TGU3enRpVVFxaWtBZXJqNWdZU042UnItTkl4d3lzcmZBYW15VW1aUEt2ZlRtUm9ubFF6aXJxWlcwV0NIOFpvNF9Ed2lyVEtfWS0zSDhPQi1jckVYeThtazBxNXFJMUQ1VzE2dnJqMXI?oc=5","date":"2025-10-09","type":"pipeline","source":"BioSpace","summary":"Ferring’s Shift to New Business Model Claims 500 Jobs Worldwide - BioSpace","headline":"Ferring’s Shift to New Business Model Claims 500 Jobs Worldwide","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5SSzVJWjlFOVRtbW1fM29scE1aNkstTE1DbzJZT1FFdDVxQjdLMUtHMGxBd2VKTXpwTEQ1WGg1eHBaOE1XaEJLQ0duaUc1eXA3d1hV?oc=5","date":"2025-10-09","type":"pipeline","source":"FirstWord Pharma","summary":"Ferring to cut 500 jobs under optimisation programme - FirstWord Pharma","headline":"Ferring to cut 500 jobs under optimisation programme","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNX1RCUEhuNU5weGlydmFVMmp6NFpFcjJLTVk0Mk40aFJSa2hybEU1RE14QVppeGF4SUM5R3BYSUFCOGVScWhiNm5qRDFJTkVrclAxVm9Tand6N2lrSzVUdkJfMXJIVDByRDczdXpST2ZHRnNMT0R5bzJEdUxaUEo5YkM5Um1QRHc?oc=5","date":"2025-10-08","type":"pipeline","source":"Fierce Pharma","summary":"Ferring to reduce global head count by 500 as part of reorganization - Fierce Pharma","headline":"Ferring to reduce global head count by 500 as part of reorganization","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTE5XZEp0UFlhM2NWWE9HTy1sakpLcy1WRF9FSzAwNDh0T1k4YlpzYXdrSGlvejlUS3RxN0VfWmFrVHhVdDF1bjBVUkZGdWRzbXFPek1sQ3JacFJxOUYwNzJPZm11dHhGVTZPQUEyTlFBOA?oc=5","date":"2025-10-08","type":"pipeline","source":"medwatch.com","summary":"Ferring Pharmaceuticals to cut global workforce by 500 - medwatch.com","headline":"Ferring Pharmaceuticals to cut global workforce by 500","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOeTZkM0RPbUVxaVZMTHQzaDBBMENuak1uRUJYb0tubThqOTNUSVgzQmE4QnFyeXNkaXlqbEg5YXV5ZDVjcTM0UTBxNkNvT240QzJQOGxnNjRfa3V1SFQ5bFdRQU12WHk4Si1Qc29saU9wNW0xNXpNb2ZhTEdOejNjNmplZWR3ZHMyZXVXOGZSWHdicS0zNlprRW53?oc=5","date":"2025-08-08","type":"pipeline","source":"Pharma Voice","summary":"As gene therapies falter on the market, this biopharma is aiming to defy the odds - Pharma Voice","headline":"As gene therapies falter on the market, this biopharma is aiming to defy the odds","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQRnhFT3VrcklfYnl3WUE4TlVQNWJkemFDblBiVWJyU3RpOUVkRXJkVTN6QUZjSUJsUmprYklZX2J1LTdWRXk2RVh4VVI0R21lWlFoZmJrNEJUMW1ramEyODRUYllmbkU4WWRSZWdzMTN0Tm44V1BVR1dhWlpBWlFnMWxuNko5SVdKT0ExWFJQeHBSTjlDZGVsS0RwcFZPREtU?oc=5","date":"2025-06-20","type":"pipeline","source":"Contract Pharma","summary":"Ferring Opens New Gene Therapy Manufacturing Facility - Contract Pharma","headline":"Ferring Opens New Gene Therapy Manufacturing Facility","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQUG5yNmdRQTZmb1d6WHo4cnpQblNaWENJT3p2cURrTVZTUlpoTnBXdl9QcU1uSGJ2aWExMDh6dmZOWVBpUC1jLUNyVWdKclJRalZrRm5XRmE4UXNueUNyLTVsRE4wNU1qckhsNmRNTGJDaUVFdVRCYmEwVjlDY1FZUFE5RFNEcmdhQkFWdWN4RXcyRmdJSk1BbUNsZ1NkOWhrTVBHQkJRai1PeXBsTHJGWQ?oc=5","date":"2025-04-25","type":"pipeline","source":"Pharmaceutical Executive","summary":"Ferring Sees Financial Success with Bladder Cancer Gene Therapy, Announces Plans for New Manufacturing Facility - Pharmaceutical Executive","headline":"Ferring Sees Financial Success with Bladder Cancer Gene Therapy, Announces Plans for New Manufacturing Facility","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQbW8wWDZUOUI5MEY2S2hGVkNmdmFNczZPUTFMWTQ0MXBrSlNoMkRiVE1lT0x3Y2ZpTWtwZDdlV01IVEh5bk1aU1kzbVdCRFpLa1ZYcFg0ZmF2akRpbTMyVEdWdXptMFlkM1NzSXVGTnVBcHBaeE83dWJmanIyeE43bGN1V2hsV1hKakp1bktoWnp5WEMzYklRTTJRamtNQUxQUGRGZWItZndSVVpmVHAyZHJsZTdrWml1UHdRd19n?oc=5","date":"2025-04-25","type":"regulatory","source":"Parsippany Focus","summary":"Ferring Pharmaceuticals Expands in Parsippany with FDA-Approved Manufacturing Hub - Parsippany Focus","headline":"Ferring Pharmaceuticals Expands in Parsippany with FDA-Approved Manufacturing Hub","sentiment":"positive"}],"patents":[],"drugCount":17,"phaseCounts":{"marketed":10,"discontinued":4,"phase_3":2,"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}